Randomized Trialhigh evidence
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
The New England journal of medicine·July 3, 2025·PMID 40353578
Why it mattersFor clinicians managing obesity pharmacotherapy, this is a direct head-to-head comparison of two leading incretin-based agents. It suggests tirzepatide offers greater weight reduction than semaglutide in non-diabetic adults, which may influence drug selection when efficacy is the main priority.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled